undamentalytics Newsletter
Sign in

Artiva Biotherapeutics, Inc. (ARTV) stock

Add to watchlist

Add holding +

NASDAQ: ARTV Nasdaq Biotechnology Next results ~November 12, 2026

Artiva Biotherapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

The Fundamentalytics view

Next results ~November 12, 2026 (estimated)

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.3bn.

Things to watch

  • Loss-making. Operating margin is -26806.4%: costs exceed revenue.
  • Burning cash. Free cash flow was -22180.9% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 2780.9% of revenue: a real cost that cash-flow figures leave out.
  • Volatile shares. Over the past year the shares showed annualised volatility of 139% and a beta of 1.7 against the S&P 500.
  • Heavily shorted. 11.1% of the shares available to trade are sold short (5.0 days of average volume to cover).
  • Missing expectations. Earnings per share fell short of the consensus estimate in 3 of the last four quarters.

Latest results: FY2024 Q4

Filed March 10, 2026
Earnings per share
-$0.63 against an average estimate of -$0.64: beat by 1.9%
Share reaction
-30.6% in the first session after the results on October 27, 2026, against +0.9% for the S&P 500
Next report
November 12, 2026; average EPS estimate -$0.53

Artiva Biotherapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day0.0%
  • 1 week-1.9%
  • 1 month-38.7%
  • This year-2.3%
  • 1 year+11.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

EPS (TTM, diluted)
$-3.21

Earnings

Last results
October 27, 2026
Next results (est.)
January 25, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Leadership
  3. Results
  4. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Artiva Biotherapeutics, Inc. valuation models and calculator

No model value for Artiva Biotherapeutics, Inc. at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 12, 2026, after the close. Analysts expect revenue of $0 and EPS of −$0.53 (range −$0.56 to −$0.47) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.64 +23% — 0%
Next −$1.98 +25% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +8.5% on 90 days ago. In the last 30 days, 1 analyst raised Artiva Biotherapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Artiva Biotherapeutics, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.43 Current fiscal year, 60 days ago: −$2.51 Current fiscal year, 30 days ago: −$2.51 Current fiscal year, 7 days ago: −$2.51 Current fiscal year, Now: −$2.64 −$2.64 Next fiscal year, 90 days ago: −$2.81 Next fiscal year, 60 days ago: −$2.61 Next fiscal year, 30 days ago: −$2.61 Next fiscal year, 7 days ago: −$2.61 Next fiscal year, Now: −$1.98 −$1.98

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.43−$2.81
60 days ago −$2.51−$2.61
30 days ago −$2.51−$2.61
7 days ago −$2.51−$2.61
Now −$2.64−$1.98

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.64 −$0.63 +1.9%
Mar 2026 −$0.84 −$0.95 −12.7%
Dec 2025 −$0.80 −$0.84 −5.0%
Sept 2025 −$0.80 −$0.88 −10.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 27, 2026

No numeric guidance in Artiva Biotherapeutics, Inc.'s latest earnings release (filed October 27, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

6 analysts, Oct 2026
Buy233%
Hold467%
Sell00%

Monthly trend

  1. Oct 2026246
  2. Sep 2026156
  3. Aug 2026156

Counts of recommendations published by analysts covering Artiva Biotherapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
11.1%
of tradable shares
Days to cover
5
at average volume
Short interest, 1 month
+33%
to October 15, 2026
Held by institutions
84%
of shares
Held by insiders
15.1%
of shares
Employees
115
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20252026 to date
Return
ARTV−57%−2%
Industry peers (median)−5%−27%
S&P 500+18%+11%
Months that ended higher
ARTV33%55%
S&P 50075%46%
Largest fall from a high during the year
ARTV−86%−69%
S&P 500−19%−9%

Worst fall since July 19, 2024: 91% from October 4, 2024 to June 27, 2025. Getting back needed a 977% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$3.07 – $13.39
From 52-week high
−68.7%
vs 50-day average
−47.5%
vs 200-day average
−47.8%
Volatility (1 year)
139%
Beta vs S&P 500
1.67

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
2 up, 8 down
typical move ±11.9%
After a week
3 up, 6 down
typical move ±12.3%
After a month
4 up, 5 down
typical move ±21.6%
Results releasedNext dayS&P 500 next day5 days21 days
October 27, 2026 −30.6% +0.9% — —
August 6, 2026 −2.8% +0.5% −2.5% −3.5%
May 8, 2026 −15.3% +1.1% −21.9% −41.9%
March 10, 2026 +24.9% −0.3% +10.7% +19.1%
November 12, 2025 −5.6% −1.6% −5.6% −8.1%
August 6, 2025 −14.3% +0.7% −13.3% +17.2%
May 8, 2025 −1.0% +0.6% +1.4% +0.5%
March 24, 2025 −6.6% +2.0% −29.7% −42.6%
November 12, 2024 −12.6% −0.3% −15.5% −20.2%
August 29, 2024 +5.6% +1.0% +10.0% +41.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Artiva Biotherapeutics, Inc.
$0 $10M $20M $30M $40M FY24 Q1 FY24 Q2 FY24 Q3 FY24 Q4 Revenue (TTM), FY24 Q1: $32.8M Revenue (TTM), FY24 Q2: $29.3M Revenue (TTM), FY24 Q3: $2.6M Revenue (TTM), FY24 Q4: $251K $251K

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY24 Q1 $32.8M
FY24 Q2 $29.3M
FY24 Q3 $2.6M
FY24 Q4 $251K
Operating margin (TTM) Artiva Biotherapeutics, Inc.
-30000% -20000% -10000% 0% FY24 Q1 FY24 Q2 FY24 Q3 FY24 Q4 Operating margin (TTM), FY24 Q1: -83.9% Operating margin (TTM), FY24 Q2: -108.8% Operating margin (TTM), FY24 Q3: -2344.8% Operating margin (TTM), FY24 Q4: -26806.4% -26806.4%

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q1 -83.9%
FY24 Q2 -108.8%
FY24 Q3 -2344.8%
FY24 Q4 -26806.4%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025
Income
Revenue 33 0 0
EBITDA −28 −65 −87
Operating income −31 −67 −90
Net income −29 −65 −84
Diluted EPS −$35.78 −$5.81 −$3.43
Growth (year on year)
Revenue — −99.3% −100.0%
Margins
EBITDA margin −84.8% <−999% —
Operating margin −91.6% <−999% —
Net margin −85.8% <−999% —
Free-cash-flow margin −151.3% <−999% —
Cash flow
Cash from operations −47 −55 −77
Capital spending 3 1 3
Free cash flow −51 −56 −79
Stock-based pay 7 7 7
Free cash flow after stock pay −58 −63 −86
Balance sheet
Cash 54 40 27
Total debt 0 0 0
Net debt (negative = net cash) −54 −40 −27
Diluted shares — 11m 24m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated ARTV CLNN CRVO CLDX CRDF IBIO Median
Revenue, last 12 months $251000 $197000 $331295 $158000 $508000 $100000 $55m
Revenue growth, last 12 months — −31.1% −95.7% −97.3% −7.0% −75.0% 12.6%
Revenue growth, 3-year average — −36.9% −52.7% −63.5% 7.2% −62.4% 13.7%
Revenue growth, latest quarter −100.0% 233.3% −100.0% −97.0% −14.0% −100.0% 10.2%
Gross margin — 70.1% 100.0% — 100.0% 59.9% 82.9%
Operating margin <−999% <−999% <−999% <−999% <−999% <−999% −191.1%
Operating margin, 3-year average — <−999% <−999% <−999% <−999% <−999% −363.5%
Net margin <−999% <−999% <−999% <−999% <−999% <−999% −172.8%
Cash from operations / revenue <−999% <−999% <−999% <−999% <−999% <−999% −168.8%
Free-cash-flow margin <−999% <−999% — <−999% <−999% <−999% −168.1%
Free-cash-flow margin, 3-year average — <−999% — <−999% <−999% <−999% −310.0%
Stock pay / revenue >999% >999% 393.0% >999% >999% >999% 20.7%
Change in share count — 35.4% 8.4% 4.7% 15.8% 13.9% 8.2%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

13F filings for June 30, 2026
Reported value
$395M
Institutions reporting
72
Shares held vs prior quarter
▲ 141.6%
Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RA Capital Management, L.P. $174M 18.0M 44.1% ▲ 82.2%
Viking Global Investors LP $25.3M 2.6M 6.4% New
Blackstone Inc. $23.3M 2.4M 5.9% —
5Am Venture Management, LLC $22.8M 2.4M 5.8% 0.0%
Venrock Adviser, LLC $19.8M 2.0M 5.0% ▲ 27.0%
Franklin Resources Inc $19.4M 2.0M 4.9% ▲ 283.8%
Caligan Partners LP $16.8M 1.7M 4.3% New
Vanguard Capital Management LLC $9.5M 982K 2.4% ▲ 372.7%
Samsara Biocapital, LLC $9.3M 955K 2.3% New
Blue Owl Capital Holdings LP $8.5M 875K 2.2% New
Propel Bio Management, LLC $6.8M 696K 1.7% ▲ 375.8%
Blackrock, Inc. $6.7M 695K 1.7% ▲ 225.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Artiva Biotherapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 25, 2027 estimated from the company's past filing pattern, not announced

  • October 27, 2026
  • August 6, 2026
  • May 8, 2026
  • March 10, 2026
  • November 12, 2025
  • August 6, 2025

Recent SEC filings

Data status

When each part of this page on Artiva Biotherapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Artiva Biotherapeutics, Inc. in brief

What does Artiva Biotherapeutics, Inc. do?
Artiva Biotherapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Artiva Biotherapeutics, Inc.'s stock ticker?
Artiva Biotherapeutics, Inc. trades under the ticker ARTV on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Artiva Biotherapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., Viking Global Investors LP and Blackstone Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Artiva Biotherapeutics, Inc.'s market cap?
On December 31, 2025, Artiva Biotherapeutics, Inc.'s market capitalisation was about $105M and net debt of -$26.7M. Market figures come from third-party market data and may be delayed.
Who are Artiva Biotherapeutics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Artiva Biotherapeutics, Inc. are Clene Inc., Cervomed Inc., Celldex Therapeutics, Inc., Cardiff Oncology, Inc. and Ibio, Inc. The side-by-side comparison below sets their revenue, margins and growth against Artiva Biotherapeutics, Inc.'s.
When is Artiva Biotherapeutics, Inc.'s next earnings date?
Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Artiva Biotherapeutics, Inc. announces its own schedule.